Caveolin contributes to the modulation of basal and β-adrenoceptor stimulated function of the adult rat ventricular myocyte by simvastatin: A novel pleiotropic effect

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Pugh, Sara D ^a   MacDougall, David A ^a   Agarwal, Shailesh R ^b   Harvey, Robert D ^b   Porter, Karen E ^a   Calaghan, Sarah ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CAVEOLIN; CAVEOLIN 3; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ISOPRENOID; NITRIC OXIDE; PHOSPHOLAMBAN; SIMVASTATIN; TROPONIN I; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; NOS3 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ARTICLE; CAVEOLA; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HEART MUSCLE CELL; INOTROPISM; LUSINOTROPY; MALE; MUSCLE CHARACTERISTICS AND FUNCTIONS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEART VENTRICLE; HUMAN; METABOLISM; MUSCLE CELL; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

RATTUS;

ADULT; ANIMALS; CAVEOLIN 3; CHOLESTEROL; GENE EXPRESSION REGULATION; HEART VENTRICLES; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MALE; MUSCLE CELLS; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; RATS; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION; SIMVASTATIN;

EID: 84907482154     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106905     Document Type: Article

References (63)

1. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd Jones DM, et al. (2013) ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. J Am Coll Cardiol doi:10.1016/j.jacc. 2013.11.002.
2. Pencina MJ, Navar-Boggan AM, D'Agostino RB, Sr., Williams K, Neely B, et al. (2014) Application of New Cholesterol Guidelines to a Population-Based Sample. N Engl J Med. doi: 10.1056/NEJMoa1315665.
3. Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S (2007) Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease. Circulation 115: 2398-2409.
4. Sadowitz B, Maier KG, Gahtan V (2010) Basic Science Review: Statin Therapy-Part I: The Pleiotropic Effects of Statins in Cardiovascular Disease. Vascular and Endovascular Surgery 44: 241-251.
5. Tousoulis D, Charakida M, Stefanadi E, Siasos G, Latsios G, et al. (2007) Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol 115: 144-150.
6. Porter KE, Turner NA (2011) Statins and myocardial remodelling: cell and molecular pathways. Expert Rev Mol Med 13: e22.
7. Werner N, Nickenig G, Laufs U (2002) Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 97: 105-116.
8. Laufs U, Liao JK (1998) Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271.
9. Urbich C, Dernbach E, Zeiher AM, Dimmeler S (2002) Double-edged role of statins in angiogenesis signaling. Circ Res 90: 737-744.
10. Nakagami H, Jensen KS, Liao JK (2003) A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med 35: 398-403.
11. Reboulleau A, Robert V, Vedie Bt, Doublet A, Grynberg A, et al. (2012) Involvement of cholesterol efflux pathway in the control of cardiomyocytes cholesterol homeostasis. J Mol Cell Cardiol 53: 196-205.
12. Feron O, Dessy C, Desager JP, Balligand JL (2001) Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103: 113-118.
13. Harvey RD, Calaghan SC (2012) Caveolae create local signalling domains through their distinct protein content, lipid profile and morphology. T Mol Cell Cardiol 52: 366-375.
14. Woodman SE, Park DS, Cohen AW, Cheung MW, Chandra M, et al. (2002) Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem 277: 38988-38997.
15. Uray IP, Connelly JH, Frazier OH, Taegtmeyer H, Davies PJ (2003) Mechanical unloading increases caveolin expression in the failing human heart. Cardiovasc Res 59: 57-66.
16. Agarwal SR, Macdougall DA, Tyser R, Pugh SD, Calaghan SC, et al. (2011) Effects of cholesterol depletion on compartmentalized cAMP responses in adult cardiac myocytes. J Mol Cell Cardiol 50: 500-509.
17. Calaghan S, White E (2006) Caveolae modulate excitation-contraction coupling and β2-adrenergic signalling in adult rat ventricular myocytes. Cardiovasc Res 69: 816-824.
18. Calaghan S, Kozera L, White E (2008) Compartmentalisation of cAMP-dependent signalling by caveolae in the adult cardiac myocyte. J Mol Cell Cardiol 45: 88-92.
19. Macdougall DA, Agarwal SR, Stepford EA, Chu H, Collins JA, et al. (2012) Caveolae compartmentalise β2-adrenoceptor signals by curtailing cAMP production and maintaining phosphatase activity in the sarcoplasmic reticulum of the adult ventricular myocyte. J Mol Cell Cardiol 52: 388-400.
20. Ziviani L, Da RL, Squassante L, Milleri S, Cugola M, et al. (2001) The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. Br J Clin Pharmacol 51: 147-152.
21. Germershausen JI, Hunt VM, Bostedor RG, Bailey PJ, Karkas JD, et al. (1989) Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun 158: 667-675.
22. Hamelin BA, Turgeon J (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19: 26-37.
23. Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D, et al. (1995) In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 131: 163-174.
24. Graham G, Stones R, White E, Harrison S, Gilbert S, et al. (2008) Microarray analysis of gene expression during adult ventricular myocye culture. Biophys J 94:501-507: 1491-Pos.
25. Bist A, Fielding PE, Fielding CJ (1997) Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol. Proc Natl Acad Sci USA 94: 10693 -10698.
26. Carozzi AJ, Ikonen E, Lindsay MR, Parten RG (2000) Role of cholesterol in developing T-tubules: analogous mechanisms for T-tubule and caveolae biogenesis. Traffic 1: 326-341.
27. Kozera L, White E, Calaghan S (2009) Caveolae act as membrane reserves which limit mechanosensitive I(Cl,swell) channel activation during swelling in the rat ventricular myocyte. PLoS One 4: e8312.
28. Muhlhauser U, Zolk O, Rau T, Munzel F, Wieland T, et al. (2006) Atorvastatin desensitizes β-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits. FASEB J 20: 785-787.
29. Laufs U, La F, V, Plutzky J, Liao JK (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135.
30. Muller-Strahl G, Kottenberg K, Zimmer HG, Noack E, Kojda G (2000) Inhibition of nitric oxide synthase augments the positive inotropic effect of nitric oxide donors in the rat heart. J Physiol 522: 311-320.
31. Massion PB, Dessy C, Desjardins F, Pelat M, Havaux X, et al. (2004) Cardiomyocyte-restricted overexpression of endothelial nitric oxide synthase (NOS3) attenuates β-adrenergic stimulation and reinforces vagal inhibition of cardiac contraction. Circulation 110: 2666-2672.
32. Balligand JL, Kobzik L, Han X, Kaye DM, Belhassen L, et al. (1995) Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J Biol Chem 270: 14582-14586.
33. Feron O, Dessy C, Opel DJ, Arstall MA, Kelly RA, et al. (1998) Modulation of the endothelial nitric-oxide synthase-caveolin interaction in cardiac myocytes. Implications for the autonomic regulation of heart rate. J Biol Chem 273: 30249-30254.
34. Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, et al. (1997) Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem 272: 25437-25440.
35. Shmeeda H, Petkova D, Barenholz Y (1995) Cholesterol distribution in rat heart myocytes. Am J Physiol 268: H759-H766.
36. Ikonen E, Heino S, Lusa S (2004) Caveolins and membrane cholesterol. Biochem Soc Trans 32: 121-123.
37. Truong TQ, Aubin D, Falstrault L, Brodeur MR, Brissette L (2010) SR-BI, CD36, and caveolin-1 contribute positively to cholesterol efflux in hepatic cells. Cell Biochem Funct 28: 480 -489.
38. Li L, Chu G, Kranias EG, Bers DM (1998) Cardiac myocyte calcium transport in phospholamban knockout mouse: relaxation and endogenous CaMKII effects. Am J Physiol 274: H1335-H1347.
39. Zheng X, Hu SJ (2005) Effects of simvastatin on cardiac performance and expression of sarcoplasmic reticular calcium regulatory proteins in rat heart. Acta Pharmacol Sin 26: 696-704.
40. Rybin VO, Xu X, Lisanti MP, Steinberg SF (2000) Differential targeting of β-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. J Biol Chem 275: 41447-41457.
41. Nichols CB, Rossow CF, Navedo MF, Westenbroek RE, Catterall WA, et al. (2010) Sympathetic stimulation of adult cardiomyocytes requires association of AKAP5 with a subpopulation of L-type calcium channels. Circ Res 107: 747 -756.
42. Kuschel M, Zhou YY, Cheng H, Zhang SJ, Chen Y, et al. (1999) G(i) protein-mediated functional compartmentaEzation of cardiac β(2)-adrenergic signaEng. J Biol Chem 274: 22048-22052.
43. Jo SH, Leblais V, Wang PH, Crow MT, Xiao RP (2002) Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent G(s) signaling during β2-adrenergic stimulation. Circ Res 91: 46-53.
44. Aravamudan B, Volonte D, Ramani R, Gursoy E, Lisanti MP, et al. (2003) Transgenic overexpression of caveolin-3 in the heart induces a cardiomyopathic phenotype. Hum Mol Genet 12: 2777-2788.
45. Ziolo MT, Kohr MJ, Wang H (2008) Nitric oxide signaling and the regulation of myocardial function. J Mol Cell Cardiol 45: 625-632.
46. Zhang YH, Casadei B (2012) Sub-cellular targeting of constitutive NOS in health and disease. J Mol Cell Cardiol 52: 341-350.
47. Zhang YH, Zhang MH, Sears CE, Emanuel K, Redwood C, et al. (2008) Reduced phospholamban phosphorylation is associated with impaired relaxation in left ventricular myocytes from neuronal NO synthase-deficient mice. Circ Res 102: 242-249.
48. Burkard N, Rokita AG, Kaufmann SG, Hallhuber M, Wu R, et al. (2007) Conditional neuronal nitric oxide synthase overexpression impairs myocardial contractility. Circ Res 100: e32-e44.
49. Xu L, Eu JP, Meissner G, Stamder JS (1998) Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 279: 234-237.
50. Seddon M, Shah AM, Casadei B (2007) Cardiomyocytes as effectors of nitric oxide signalling. Cardiovasc Res 75: 315-326.
51. Wang H, Kohr MJ, Wheeler DG, Ziolo MT (2008) Endothelial nitric oxide synthase decreases β-adrenergic responsiveness via inhibition of the L-type Ca2+ current. Am J Physiol Heart Circ Physiol 294: H1473-H1480.
52. Mizuguchi Y, Oishi Y, Miyoshi H, Iuchi A, Nagase N, et al. (2008) Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia. Circ J 72: 538-544.
53. Talini E, Di Bello V, Bianchi C, Palagi C, le Donne MG, et al. (2008) Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin A preliminary echocardiographic study. Atherosclerosis 197: 346-354.
54. Bountioukos M, Rizzello V, Krenning BJ, Bax JJ, Kertai MD, et al. (2003) Effect of atorvastatin on myocardial contractile reserve assessed by tissue Doppler imaging in moderately hypercholesterolemic patients without heart disease. AmJ Cardiol 92: 613-616.
55. Rubinstein J, Aloka F, Abela GS (2009) Statin therapy decreases myocardial function as evaluated via strain imaging. Clin Cardiol 32: 684-689.
56. Bristow MR (1993) Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 22: 61A-71A.
57. Foerster K, Groner F, Matthes J, Koch WJ, Birnbaumer L, et al. (2003) Cardioprotection specific for the G protein Gi2 in chronic adrenergic signaling through β2-adrenoceptors. Proc Natl Acad Sci USA 100: 14475-14480.
58. Chesley A, Lundberg MS, Asai T, Xiao RP, Ohtani S, et al. (2000) The β(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase. Circ Res 87: 1172 -1179.
59. Calaghan SC, White E, Colyer J (1998) Co-ordinated changes in cAMP, phosphorylated phospholamban, Ca2+ and contraction following β-adrenergic stimulation of rat heart. Pflugers Arch 436: 948-956.
60. Leach RN, Desai JC, Orchard CH (2005) Effect of cytoskeleton disrupters on L-type Ca channel distribution in rat ventricular myocytes. Cell Calcium 38: 515 -526.
61. Norman AW, Demel RA, de KB, van Deenen LL (1972) Studies on the biological properties of polyene antibiotics. Evidence for the direct interaction of filipin with cholesterol. J Biol Chem 247: 1918-1929.
62. Hatcher CJ, Godt RE, Nosek TM (1999) Excessive microtubules are not responsible for depressed force per cross-bridge in cardiac neural-crest-ablated embryonic chick hearts. Pflugers Archiv Eur J Physiol 438: 307-313.
63. Nussler AK, Glanemann M, Schirmeier A, Liu L, Nussler NC (2006) Fluorometric measurement of nitrite/nitrate by 2,3-diaminonaphthalene. Nat Protoc 1: 2223-2226.